Revilab SL 01 is a sublingual multi-peptide formulation belonging to the Revilab product line developed under the direction of Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.

Overview

The Revilab SL line represents an evolution of Khavinson's bioregulator concept from single-tissue preparations toward multi-target combination formulations. The underlying principle is that aging affects multiple organ systems simultaneously, and optimal geroprotective intervention should address multiple tissue types concurrently. Khavinson's decades of research on tissue-specific peptide bioregulators (Khavinson, 2002) demonstrated that short peptides (2-4 amino acids) can regulate gene expression in a tissue-selective manner by interacting with specific DNA sequences at gene promoter regions.

Revilab SL 01 combines peptides with reported activity in cardiovascular tissue, nervous system tissue, and immune system regulation. The sublingual delivery route bypasses first-pass hepatic metabolism and gastrointestinal degradation, potentially improving bioavailability of the constituent peptides compared to oral capsule formulations.

The Revilab SL series comprises multiple numbered formulations (SL 01 through SL 10), each targeting a different combination of organ systems. SL 01 focuses on the cardiovascular-neuro-immune axis, reflecting the interconnected decline of these systems during aging.

Mechanism of Action

Multi-Target Peptide Bioregulation

Each constituent peptide in Revilab SL 01 is proposed to act through the established Khavinson mechanism: penetration into cell nuclei and direct interaction with DNA at tissue-specific gene promoter regions, modulating transcription of proteins involved in tissue maintenance and repair (Khavinson et al., 2021). The combination approach delivers multiple tissue-specific signals simultaneously, potentially creating synergistic effects across interconnected physiological systems.

Sublingual Absorption

The sublingual delivery route exploits the highly vascularized mucosa beneath the tongue for direct absorption of short peptides into the systemic circulation. For peptides of 2-4 amino acids, this route offers advantages over oral administration: avoidance of gastric acid degradation, bypass of hepatic first-pass metabolism, and rapid onset of systemic distribution. The small molecular size of the constituent peptides is well-suited to transmucosal absorption.

Cardiovascular Component

The cardiovascular-targeting peptides in the formulation are proposed to act on cardiomyocytes and vascular endothelium, modulating gene expression involved in cardiac contractility, vascular tone, and tissue remodeling. This is consistent with research on Cardiogen (Ala-Glu-Asp-Arg), which has demonstrated effects on cardiac fibroblast activity and cardiomyocyte proliferation in aging tissue (Khavinson et al., 2012).

Neuroprotective Component

The neurological peptide components are proposed to support neuronal survival, synaptic plasticity, and neurotransmitter balance. Research on pineal and brain-derived peptide bioregulators has demonstrated neuroprotective effects through modulation of apoptotic pathways and antioxidant gene expression in neuronal tissue. Related research on Cortagen and Pinealon provides context for the neurological mechanisms involved.

Immune Component

The immune-targeting peptides in the formulation are proposed to support immune cell function through mechanisms similar to those documented for Vilon (Lys-Glu) and thymic peptide preparations. This may include modulation of T-cell function, cytokine balance, and innate immune activity.

Reconstitution Calculator

Research

Safety Profile

Revilab SL 01 has been used in Russia as part of anti-aging bioregulator protocols without significant adverse effects reported in available literature. The constituent peptides are short (2-4 amino acids) and composed of naturally occurring amino acids, suggesting rapid metabolism and minimal accumulation. The sublingual delivery route avoids gastrointestinal side effects associated with some oral peptide preparations. However, formal Western-standard clinical trials with rigorous safety endpoints have not been published. The multi-target nature of the formulation introduces theoretical complexity in predicting interactions. Individuals with cardiovascular conditions on medication should consult their physician, as bioregulatory effects on cardiac tissue could theoretically interact with cardiovascular drugs. No formal drug interaction studies have been conducted.

Pharmacokinetic Profile